Other News To Note
• Durata Therapeutics Inc., of Morristown, N.J., reported in vitro data that could help support a clinical program testing antibiotic candidate dalbavancin in pneumonia. In the study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin. Results were presented at IDWeek in San Diego.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter